Ravindra K. Pandey - Williamsville NY, US Amy Gryshuk - Pleasanton CA, US Lalit Goswami - Amherst NY, US William Potter - Grand Island NY, US Allan Oseroff - Buffalo NY, US
Assignee:
Health Research, Inc. - Buffalo NY
International Classification:
A61B 5/055
US Classification:
424 93, 424 961, 514279, 514410
Abstract:
A tetrapyrollic photosensitizer compound having at least one pendant —CHCHCON(CHCON(CHCOOH))or —N(CHCOOH)group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula:.
Multi Dtpa Conjugated Tetrapyrollic Compounds For Phototherapeutic Contrast Agents
Ravindra K. Pandey - Williamsville NY, US Lalit Goswami - Amherst NY, US Joseph Spernyak - West Seneca NY, US Peter Kanter - East Aurora NY, US Richard Mazurchuk - Clarence Center NY, US
Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e. g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3 to 6 —CHCONHphenylCHCH(N(CHCOOH)))(CHN(CHCOOH)(CHCHN(CHCOOH))) groups or esters thereof or complexes thereof with gadolinium(III).
Water Soluble Tetrapyrollic Photosensitizers For Photodynamic Therapy
Ravindra Pandey - Williamsville NY, US Amy Gryshuk - Pleasanton CA, US Lalit Goswami - Amherst NY, US William Potter - Grand Island NY, US Allan Oseroff - Buffalo NY, US
Assignee:
Health Research, Inc. - Buffalo NY
International Classification:
A61K 31/555 C07D 487/22 A61K 31/409
US Classification:
514185000, 540145000, 514410000
Abstract:
A tetrapyrollic photosensitizer compound having at least one pendant —CHCHCON(CHCON(CHCOOH))or —N(CHCOOH)group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a pharmaceutically acceptable derivative thereof, wherein R-Rand Rare various substituents and Ris substituted or unsubstituted —CHCHCON(CHCON(CHCOOH)); or —N(CHCOOH). The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
Water Soluble Tetrapyrollic Photosensitizers For Photodynamic Therapy
Ravindra K. Pandey - Williamsville NY, US Amy Gryshuk - Pleasanton CA, US Lalit Goswami - Amherst NY, US William Potter - Grand Island NY, US Allan Oseroff - Buffalo NY, US
Assignee:
Health Research, Inc. - Buffalo NY
International Classification:
A61K 49/00 A61P 35/00
US Classification:
424 961, 424 96
Abstract:
A tetrapyrollic photosensitizer compound having at least one pendant —CHCHCON(CHCON(CHCOOH))or —N(CHCOOH)group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula:or a pharmaceutically acceptable derivative thereof, wherein R—Rand Rare various substituents and Ris substituted or unsubstituted —CHCHCON(CHCON(CHCOOH)); or —N(CHCOOH). The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
Multimodality Agents For Tumor Imaging And Therapy
Ravindra K. Pandey - Williamsville NY, US Suresh Pandey - Buffalo NY, US Lalit Goswami - Columbia MO, US Allan Oseroff - Buffalo NY, US Shipra Dubey - Williamsville NY, US Munawwar Sajjad - Clarence Center NY, US Stephanie Pincus - Buffalo NY, US
Assignee:
HEALTH RESEARCH, INC. - Buffalo NY THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK - Amherst NY
A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is C, F, Cu, I, Tc, In or GdIII and its method of use for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors. Preferably the photosensitizer is a tumor avid tetrapyrollic photosensitizer, e.g. a porphyrin, chlorin or bacteriochlorin, e.g. pheophorbides and pyropheophorbides. Such conjugates have extreme tumor avidity and can be used to inhibit or completely destroy the tumor by light absoption. The integrin is usually αvβ3, α5β1, αvβ5, α4β1, or α2β1. Preferably, the antagonist is an RGD peptide or another antagonist that may be synthetic such as a 4-{2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethyloxy}-benzoyl]amino-2-(S)-amino-ethyl-sulfonylamino group. Such compounds provide tumor avidity and imaging ability thus permitting selective and clear tumor imaging.
Silica Nanoparticles Postloaded With Photosensitizers For Drug Delivery In Photodynamic Therapy
Ravindra K. Pandey - Williamsville NY, US Lalit N. Goswami - Columbia MO, US Allan Oseroff - Buffalo NY, US Stephanie Pincus - Buffalo NY, US Janet Morgan - Buffalo NY, US Paras N. Prasad - Williamsville NY, US Earl J. Bergey - South Dayton NY, US
Assignee:
The Research Foundation on State University of NY - Amherst NY Health Research, Inc. - Buffalo NY
A nanoparticle including a polysiloxane base having an exterior surface and having a photosensitizer at least partly exposed at its exterior surface, said photosensitizer being secured to the exterior surface by loading the photosensitizer onto the surface after formation of the polysiloxane base of the nanoparticle. The nanoparticle may have tumor targeting moieties and may be post loaded with cyanine dye. The nanoparticle preferably includes post loaded moieties providing at least two of tumor specificity, photodynamic properties and imaging capabilities and the photosensitizer is tagged with a radioisotope. A method for preparation of the nanoparticle is also provided.
Multimodality Agents For Tumor Imaging And Therapy
Lalit Goswami - Columbia MO, US Allan Oseroff - Buffalo NY, US Shipra Dubey - Williamsville NY, US Munawwar Sajjad - Clarence Center NY, US
Assignee:
The Research Foundation of State University of New York - Amherst NY Health Research, Inc. - Buffalo NY
International Classification:
C07K 7/06
US Classification:
530330
Abstract:
A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is C, F, Cu, I, Tc, In or GdIII and its method of use for diagnosing, imaging and/or treating hyperproliferative tissue such as tumors. Preferably the photosensitizer is a tumor avid tetrapyrollic photosensitizer, e.g. a porphyrin, chlorin or bacteriochlorin, e.g. pheophorbides and pyropheophorbides. Such conjugates have extreme tumor avidity and can be used to inhibit or completely destroy the tumor by light absorption. The integrin is usually αvβ3, α5β1, αvβ5, α4β1, or α2β1. Preferably, the antagonist is an RGD peptide or another antagonist that may be synthetic such as a 4-{2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethyloxy}-benzoyl]amino-2-(S)-amino-ethyl-sulfonylamino group. Such compounds provide tumor avidity and imaging ability thus permitting selective and clear tumor imaging.
- Columbia MO, US Lalit N. Goswami - Columbia MO, US Marion F Hawthorne - Columbia MO, US Satish S. Jalisatgi - Columbia MO, US
International Classification:
C07D 401/08 C07C 211/63 A61P 21/00
Abstract:
Disclosed herein are carborane derivatives of Formula I or Formula V, or a pharmaceutically acceptable salt thereof, for use as neuromuscular blocking agents. The carborane is substituted with two cationic functional groups selected from amines that form ammonium cations, ethers and/or alcohols that form oxonium cations, sulfides and/or thiols that form sulfonium cations, and phosphanes and/or phosphines that form phosphonium cations.
Boehringer Ingelheim
Senior Scientist-Bioanalytical
Merial, A Sanofi Company 2015 - Dec 2016
Senior Scientist-I
University of Missouri 2010 - 2015
Group Leader-Biomedical Synthesis
University of Missouri 2007 - 2010
Senior Postdoctoral Fellow
University at Buffalo 2006 - 2007
Postdoctoral Fellow-Part Time
Education:
Central Drug Research Institute (Cdri) Lucknow, India 1999 - 2004
Doctorates, Doctor of Philosophy, Philosophy, Chemistry
Kumaun University 1997 - 1999
Master of Science, Masters, Chemistry
Kumaun University 1994 - 1997
Bachelors, Biology, Chemistry
Central Drug Research Institute (Cdri) Lucknow
Skills:
Drug Discovery Characterization Purification Organic Chemistry Organic Synthesis Analytical Chemistry Chemistry Fluorescence Nanoparticles Medicinal Chemistry Drug Design Formulation Hplc Diagnostic Imaging Probes For Optical/Mri/Ct/X Ray/Pet Mri Contrast Agents Multimodality Imaging Probes Biosensors Heterocyclic Chemistry Heterobifunctional Linkers Amino Acids and Peptides Theranostic Agents Nanomedicine Drug Delivery Bioconjugate Chemistry Targeted Drug Delivery Dendrimers Polymers Liposomes Synthetic Methadology Cancer Polymers Science High Performance Liquid Chromatography Bioanalysis Liquid Chromatography Mass Spectrometry Analytical Method Validation Good Laboratory Practice Lcms Nuclear Magnetic Resonance Pharmacokinetics Fda Cvm
Languages:
English Hindi
Certifications:
Advance Lcms Troubleshooting Training Certificate-2017 Bio Safety Officer Certificate-2017 Solid-Phase Microextraction (Spme) Training Certificate-2016 Watson-Lims
Sep 2010 to 2000 Group LeaderI2NM2, University of Missouri (MU)
Feb 2010 to 2000 Research Assistant ProfessorI2NM2, MU Columbia, MO Jul 2007 to Jan 2010 Research AssociateSUNY at Buffalo (UB) Buffalo, NY Feb 2006 to Jun 2007 Post-doctoral fellow-Part timeRoswell Park Cancer Institute (RPCI) Buffalo, NY Jul 2004 to Jun 2007 Post-doctoral fellow
Education:
Central Drug Research Institute Lucknow, Uttar Pradesh 2004 Ph.D. in Medicinal/Synthetic Organic ChemistryKumaun University-Nainital Naini Tal, Uttarakhand 1999 MS in ChemistryKumaun University-Nainital Naini Tal, Uttarakhand 1997 BS in Chemistry-Biology
Sep 2010 to 2000 Group LeaderI2NM2, University of Missouri (MU)
Feb 2010 to 2000 Research Assistant ProfessorI2NM2, MU Columbia, MO Jul 2007 to Jan 2010 Research AssociateSUNY at Buffalo (UB) Buffalo, NY Feb 2006 to Jun 2007 Post-doctoral fellow-Part timeRoswell Park Cancer Institute (RPCI) Buffalo, NY Jul 2004 to Jun 2007 Post-doctoral fellow
Education:
Central Drug Research Institute Lucknow, Uttar Pradesh 2004 Ph.D. in Medicinal/Synthetic Organic ChemistryKumaun University-Nainital Naini Tal, Uttarakhand 1999 MS in ChemistryKumaun University-Nainital Naini Tal, Uttarakhand 1997 BS in Chemistry-Biology